Ad Blocker Detected
Our website is made possible by displaying online advertisements to our visitors. Please consider supporting us by disabling your ad blocker.
ICICI Direct’s research report on Zydus Wellness
Zydus Wellness (ZWL) announced a ₹1100 crore fund raising with ₹350 crore infusion by promoter and ₹750 crore by QIB placement of equity/equivalent instruments.
We believe the company would utilise funds to repay high cost debt of ₹1500 crore that was raised at the time of acquisition of the Heinz business. With equity infusion of ₹1100 crore, existing cash of ₹200 crore, FY21 earnings, ZWL would be able to repay almost entire debt by March 2021.
This would result in saving of ₹140 crore interest cost. Assuming equity infusion at current price of ₹1650/share (given promoters have infused ₹350 crore at ₹1643/share), the equity dilution would be ~12%. The mere saving of interest cost would increase our FY22 EPS estimate by 21%.